Whistle-blower: Walgreen saw "unique opportunity" to substitute more expensive meds

09/13/2011 | BNET

A whistle-blower lawsuit accuses Walgreen executives of encouraging pharmacists to switch patients' Zantac tablet prescriptions to a Par Pharmaceuticals capsule version that cost up to three times as much. Par representatives alerted Walgreen managers that Medicaid limited reimbursement for the tablet version but not for the capsule version. Walgreen's director of pharmacy marketing allegedly told pharmacists that substituting the easier-to-swallow capsules for the tablets was "a unique opportunity" to interact with patients.

View Full Article in:

BNET

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN